Polku Therapeutics is pleased to announce the award of a grant from the Alzheimer’s Association and the Rainwater Charitable Foundation under the Tau Pipeline Enabling Program (T-PEP) and an investment from Alzheimer’s Drug Discovery Foundation’s Therapeutics Funding Program. The funding will support Polku’s innovative approach to developing new treatments for tauopathies, including Alzheimer’s disease and frontotemporal dementia.
Polku Therapeutics
Biotechnology Research
A path toward effective therapies for neurodegenerative disorders
About us
Polku Therapeutics Oy is carving a new path to a healthy aging brain by developing innovative, disease-modifying therapies for neurodegenerative diseases. By targeting key pathways involved in protein aggregation and neuroinflammation, Polku aims to deliver breakthrough treatments for conditions such as Parkinson's Disease, Alzheimer’s, and frontotemporal dementia.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Type
- Privately Held
Employees at Polku Therapeutics
-
Rouslan Michtchenko
Creating Value through Strategic Partnering and Investment in Early Drug Discovery
-
Sebastian Soidinsalo
Founder & Director of Operations
-
Sara Kangaspeska
Investment Director at Innovestor Life Science & Health Fund. Board Member at Finnish Bioindustries.
-
Bendegúz Áron Varga
R&D specialist at Polku Therapeutics
Updates
-
We're #hiring a new Drug Discovery R&D Specialist ideal for a fresh biomed graduate preferably in Helsinki. Apply today or share this post with your network.